Harnessing the Power of Autophagy
to Restore Health and Cure Disease
PAQ’s global team is pioneering a new approach to restoring health and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins.
PAQ’s platform is driven by autophagosome-tethering compounds (ATTECs), small molecules with the potential to catalyze and selectively enhance the degradation of disease-causing entities through autophagy. Using this powerful platform, PAQ has the potential to identify and design novel therapies to deliver on the promise of autophagy with the goal of overcoming serious diseases that have limited or no treatment options.
PAQ’s initial focus is on a genetic neurodegenerative disorder with no current treatment options for patients. PAQ plans to expand the ATTEC platform to target additional disease-causing protein and non-protein targets.
PAQ’s expert team of global scientists, entrepreneurs and world-class scientific advisors are committed to broadening therapeutic horizons driven by advances in autophagy.
Based in Cambridge, Massachusetts, our team is visionary, enthusiastic and united in our commitment to help patients overcome devastating disease through the power of autophagy. Join us as we work together to achieve the full potential of our research and realize the promise of a new therapeutic approach for patients.Learn more about open positions
News & Media
Learn more about PAQ and its ATTEC platform.
to Develop Novel Therapies through Autophagy-Dependent Degradation
100 Summit Drive, Suite 916
Burlington, MA 01803, USA
Interest in PAQ?
We’d like to hear from you.